General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(MODEST), Amgen Inc. ( Ended January 2021 )(NONE), Boehringer-Ingelheim ( Ended January 2021 )(NONE), Edwards ( Ended December 2020 )(NONE), Merck & Co., Inc. ( Ended November of 2020 )(NONE)

View Full Disclosure